


## JUNO VAPE



## Juno Vape Product Information



## Product details

Schedule	8
TGA Category	5
Product form	Inhalation, single use vaporiser
Cultivar	Libras
Flower Category	Indica dominant
Product size unit	1.0g



## Terpene analysis

Flavour/aroma profile	Spicy and earthy base, softened by floral and sweet accents
Total terpene content	2.68%



## Cannabinoid profile

Total THC	340mg/g
Total CBD	500mg/g
Total CBG	≤ 30mg/g
Total CBN	≤ 30mg/g



## Pharmacokinetic Considerations

Onset of action <sup>1</sup>	5–10 mins
Duration <sup>1,2</sup>	2–4 hours
Bioavailability <sup>1</sup>	10–60%

## Proposed dosing strategies for Australian Natural Range

A general approach to cannabis vaporisers is to 'start low, go slow, and stay low'.<sup>1-3</sup> Optimising the dose for the patient, where the therapeutic effect is maximised and adverse effects are minimised, requires patients and doctors to work together to determine the effectiveness of the chosen product for the patient and their medical condition.<sup>2</sup>

Australian Natural Vape Products need to be heated prior to administration to convert tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA) found in the vape product, into the active form of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Cannabis therapy is highly individualised. Cannabis dosages and titrations will be established by the prescribing doctor depending on the content of THC and CBD in the vape preparations, the route of administration and the risk/benefit ratio.

For vaporiser inhalation, patients should start with 1 inhalation, drawing in an inhalation and then waiting 15 min. Then, they may increase by 1 inhalation every 15–30 min until desired symptom control has been achieved.<sup>1</sup> Vaporisation can be utilised as an add-on PRN technique for episodic exacerbations of symptoms where appropriate.<sup>1</sup>

It should be noted that dose escalation is not generally observed.<sup>1</sup> It is advised that if doses higher than those outlined above are required, this requires medical re-assessment.<sup>1</sup> As such, a maximum dose of THC should not exceed careful titration, with doses of 20-30mg of THC per day potentially increasing the presentation of adverse events.<sup>1</sup>

## Cessation Guidelines

Medicinal cannabis vape products should be ceased if the following criteria are met:

- the desired clinical effect is not apparent after 4–12 weeks; and
- psychoactive or other side-effects are prohibitive (particularly for THC preparations).<sup>3</sup>

### REFERENCES

1. MacCallum, C.A. and Russo, E.B. Practical considerations in medical cannabis administration and dosing. *Eur J Intern Med*, 2018. 49: p. 12-19.
2. Clinical Guidance: for the use of medicinal cannabis products in Queensland. March 2017. Queensland Health. Queensland Government, Australia
3. Guidance for the use of medicinal cannabis in Australia: Overview. Therapeutic Goods Administration. Australian Government. Available from: <https://www.tga.gov.au/sites/default/files/guidance-use-medicinal-cannabis-australia-overview.pdf>.